Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969017 | 0.85 | NPSR1 (0.76) | NPSR1LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL7562796 | 0.83 | NPSR1 (1.00) | NPSR1LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL12301766 | 0.81 | NPSR1 (0.69) | NPSR1LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL7369250 | 0.80 | F2 (0.49) | NPSR1 | |
| SCHEMBL7369254 | 0.80 | F2 (0.49) | NPSR1 | |
| SCHEMBL30808619 | 0.79 | NPSR1 (0.67) | NPSR1LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL4971618 | 0.79 | NPSR1 (0.67) | NPSR1LMNAALDH1A1ALOX15TSHR | |
| SCHEMBL10465762 | 0.78 | NPSR1 (0.49) | NPSR1ALDH1A1TSHRGFERPOLB | |
| SCHEMBL5966758 | 0.77 | CCKBR (0.48) | — | |
| SCHEMBL16553787 | 0.77 | BCHE (0.65) | NPSR1LMNAALDH1A1TSHRBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403444-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | UNIV GEORGIA STATE RES FOUND (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210403444-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | UNIV GEORGIA STATE RES FOUND (US) | 2021-12-30 | — | — | US | disclosed |
| US-11084796-B2 | Heterocyclic derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084796-B2 | Heterocyclic derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20190135770-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190135770-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3454896-A1 | HETEROCYCLIC DERIVATIVES FOR THE THRATMENT OF RSV | Georgia State University Research Foundation, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017196970-A1 | HETEROCYCLIC DERIVATIVES FOR THE THRATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017196970-A1 | HETEROCYCLIC DERIVATIVES FOR THE THRATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135770-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | MAVS, HMGB3, NIPSNAP3A | NPSR1 2596/4885LMNA 2111/4885ALDH1A1 3430/4885 |
| US-20210403444-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | MAVS, HMGB3, NIPSNAP3A | NPSR1 2596/4885LMNA 2111/4885ALDH1A1 3430/4885 |
| US-11084796-B2 | Heterocyclic derivatives for the treatment of RSV | MAVS, HMGB3, NIPSNAP3A | NPSR1 2596/4885LMNA 2111/4885ALDH1A1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.